Australia's largest stock trading and investment forum Australia's #1 stock forum

KZA

Click for more information

0.00%

8.0¢ kazia therapeutics limited

TRXE-002-1 (Cantrixil) Toxicology, page-6

First 6 Last

Jazzasax

3,137 Posts.

383

16/04/16

12:30

Post #: 17520183

Originally posted by Ninja_Chook ↑

At long last the abstract for the Cantrixil Toxicology presentation is out.

No nasty surprises in it.

The conclusion says it all, "These data show that TRXE-002-1 has an acceptable toxicity profile in rats and dogs, and is without genotoxicity and cardiotoxicity at clinically relevant concentrations."

Here it is:

Column 1

1 Introduction: TRXE-002-1 is a low molecular weight super benzopyran molecule identified as having potent activity against many cancer phenotypes. It was identified from a library of analogues as being able to induce cell death in both chemoresistant CD44+/MyD88+ ovarian cancer stem cells (IC50 of ~ 50 nM) and chemosensitive CD44-/MyD88- ovarian cancer cells, and disrupt spheroid cultures formed from cancer stem cells. In vivo studies have confirmed efficacy in a rodent intra-peritoneal model of human ovarian cancer. Here we report on pre-clinical toxicology studies conducted on TRXE-002-1.Method: We conducted a full GLP dog CV study using a 4X4 Latin Square Crossover study design where we assessed telemetric ECG recordings from 4 male dogs post IP administration at doses up to 30 mg/kg. Thirty seconds of continuous ECG tracings were collected pre-dose (Baseline) and at 0.5, 1.5, 2.5, and, 24 hours after test article or vehicle administration. In addition, TRXE-002-1 was assessed in standard assays used to identify mutagenic potential using the bacterial reverse mutation assay. The potential for TRXE-002-1to induce micronuclei in the bone marrow of SPF Arc(S) Swiss mice was also investigated as a measure of clastogenicity. TRXE-002-1 toxicology was evaluated in MTD, and 28-day repeat dose GLP studies in rats and dogs.Results: TRXE-002-1 was found to have no effect on cardiac parameters of blood pressure and electrocardiography in dogs. TRXE-002-1 had no reverse mutagenic potential using the bacterial reverse mutation pre-incubation method ± S9 metabolic activation (Salmonella typhimurium strains TA98, TA100, TA1535, TA1537, and the WP2 uvrA Escherichia coli strain). Similarly, TRX-E-002-1 was shown to be non-mutagenic using the gene mutation test at the TK locus in L5178Y mouse lymphoma cell culture with and without metabolic activation. High doses of TRXE-002-1 (200 and 400 mg/kg) caused a significant increase in incidence of micronuclei in male and female mice. Repeat intraperitoneal injection of TRXE-002-1 to male and female dogs and rats over 28 days was well tolerated. Adverse TRXE-002 1-related effects were limited to microscopic findings in the testes and epididymides for male rats and dogs at high doses. Macroscopic observations at necropsy were confined to sporadic distention of the cecum and colon and colon obstruction in rats only (high dose) with no observed gastrointestinal microscopic findings reported in either species. Other observations were mostly resolved after a 14-day recovery period, except microscopic findings in the testes from both species.Conclusion: These data show that TRXE-002-1 has an acceptable toxicity profile in rats and dogs, and is without genotoxicity and cardiotoxicity at clinically relevant concentrations. TRXE-002-1 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for ovarian cancer and a first-in-human clinical trial is planned for 2016.

http://www.abstractsonline.com/Plan...971&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267

Bring on the trials!

Expand

Thanks for reporting NC

I guess you couldn't hope for better results going into human trials! This also bodes very well for Trilexium and all the other Superbenzopyrans that we have, including the non Oncology potential!

No doubt each of those will require their own toxicology but this pretty much means they will get through without any toxic outcomes at good efficacy! So far the chemistry here has not had ANY negative outcomes, no set backs or problems. We just seem to keep finding better versions of the earlier one's so what we eventually end up with when we go through all the Clinical Phases is an exciting potential IMO!

I think this is a major step forward for this platform and should not be underestimated for the future potential of Novogen's success and therefore a cure or breakthrough in the treatment of cancer!!!

YOU BLOODY BEAUTY!!!

NRT Price at posting: 13.0¢ Sentiment: Buy Disclosure: Held

0 Great analysis

Top Stories

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Bitcoin investors need to know the risks

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

ASX hits all time high out the gate on Friday trades following bullish US inflation data

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

There are more pages in this discussion • 45 more messages in this thread...

First 6 Last

Add KZA (ASX) to my watchlist